Filing Flows › Health Care › Gilead Sciences (GILD)
Gilead Sciences (GILD) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · Gilead Sciences (GILD) Q3 2026 earnings results →
Q3 2026 Revenue up 7% year over year to $8.3B · 29¢ of every $1 of revenue kept as net profit · operating margin 41.7%
Gilead Sciences made $8.3B in Q3 2026 (+7% Y/Y): Total HIV $6.3B, Trodelvy $506M, Total Cell Therapy $355M. Operating margin 41.7%, net earnings $2.4B. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $8.3B in Q3 2026, up 7% year over year and up 6% from the previous quarter. Biktarvy was the largest line at 49% of revenue. Biktarvy added $0.37B year over year (up 10%), 70% of the total change. Total Cell Therapy declined 18%.
Operating profit was $3.5B, a 41.7% margin (down 1.1 points year over year). Of the extra revenue versus Q3 2025, 25% reached operating profit, below the 43% margin then. Total costs grew 9% against revenue growth of 7%. The fastest-growing cost line was SG&A (+21%). Net earnings were $2.4B, down 20% year over year. The effective tax rate was 20.7%.
Operating cash flow was $5.0B (up 23% year over year), 207% of net earnings. Non-cash charges added back $0.13B of depreciation and $0.23B of share-based compensation. Working capital and other items added $2.2B. After purchases of property, plant and equipment ($0.24B), free cash flow as the company reports it was $4.8B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $8.3B | +7% | 41.7% | $2.4B | $5.0B |
| Q2 2026 | 10-Q | Aug 6, 2026 | $7.8B | +10% | -133.2% | −$10.5B | $3.6B |
| Q1 2026 | 10-Q | May 7, 2026 | $7.0B | +4% | 37.2% | $2.0B | $2.5B |
| Q4 2025 | 10-K | Feb 24, 2026 | $7.9B | +5% | 25.0% | $2.2B | $3.3B |
| Q3 2025 | 10-Q | Nov 7, 2025 | $7.8B | +3% | 42.8% | $3.1B | $4.1B |
| Q2 2025 | 10-Q | Aug 7, 2025 | $7.1B | +2% | 34.9% | $2.0B | $827M |
| Q1 2025 | 10-Q | May 7, 2025 | $6.7B | -0.3% | 33.6% | $1.3B | $1.8B |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Cardinal Health, Inc. (“Cardinal Health”) — 29% of its revenue · Stated in 10-K (XBRL) · source
- McKesson Corporation (“McKesson”) — 24% of its revenue · Stated in 10-K (XBRL) · source
- Cencora, Inc. (“Cencora”) — 21% of its revenue · Stated in 10-K (XBRL) · source
About Gilead Sciences
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.
In its own words, from its 10-K, filed Feb 24, 2026.
Gilead Sciences against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +7% against the peers' median +11%. Operating margin: 41.7% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
| TECH Bio-Techne | Q1 FY27 | $300M | +5% | 12.2% |
Source: Gilead Sciences 10-Q on SEC EDGAR · CIK 882095 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns GILD and who is buying
More on GILD
- How Gilead Sciences makes money: revenue by segment
- Gilead Sciences next earnings date and what analysts expect
- Gilead Sciences stock forecast, price target and fair value
- Who owns Gilead Sciences stock: holders, funds and Congress trades
- Gilead Sciences guidance and outlook
- Is Gilead Sciences a takeover target? LBO and rumors
- Gilead Sciences recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Gilead Sciences guidance history: guided vs reported
- Gilead Sciences operating margin by quarter
- Gilead Sciences net income by quarter
- Gilead Sciences free cash flow by quarter
- Gilead Sciences R&D spending by quarter
- Gilead Sciences capital expenditures by quarter
- Gilead Sciences Total HIV revenue by quarter
- Gilead Sciences Trodelvy revenue by quarter
- Gilead Sciences Total Cell Therapy revenue by quarter